Ian M. Waxman
Bristol-Myers Squibb (United States)
2 papers in the Anchorcite directory, published between 2014 and 2015, cited 11,561 times in total.
Research topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Renal cell carcinoma treatment · 1 paper
- Ferroptosis and cancer prognosis · 1 paper
- Cutaneous Melanoma Detection and Management · 1 paper
- Melanoma and MAPK Pathways · 1 paper
Frequent co-authors
- Robert John Motzer · 1 paper
- Bernard J. Escudier · 1 paper
- David F. McDermott · 1 paper
- Saby George · 1 paper
- Hans J. Hammers · 1 paper
- Sandhya Srinivas · 1 paper
- Scott S. Tykodi · 1 paper
- Jeffrey Alan Sosman · 1 paper
Papers
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…
- Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…
Metadata from OpenAlex (CC0).